FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892029871> ?p ?o ?g. }

• W2892029871 endingPage "4099" @default.
• W2892029871 startingPage "4099" @default.
• W2892029871 abstract "4099 Background: Addition of oral leucovorin (LV) to S-1 significantly improved progression-free survival (PFS) in a previous randomized phase II trial in Japanese patients (pts) with gemcitabine (GEM)-refractory advanced pancreatic cancer (PC). TAS-118 is an oral drug containing S-1 and LV. This phase III trial conducted in Japan and Korea compared overall survival (OS) between GEM-refractory advanced PC pts treated with TAS-118 and S-1. Methods: GEM-refractory PC pts were randomized in a 1:1 ratio to receive TAS-118 (S-1; 40-60 mg and LV; 25 mg bid for 1w, q2w) or S-1 (S-1; 40-60 mg bid for 4w, q6w). The primary endpoint was OS. The secondary endpoints included PFS, overall response rate, disease control rate, duration of response, and safety. Results: Five hundred and eighty-six pts were eligible for efficacy assessment (TAS-118: n=296 and S-1: n=290). Baseline characteristics were well balanced between the treatment arms. TAS-118 did not result in a statistically significant improvement in OS compared with that achieved with S-1 (median OS, 7.6 months vs. 7.9 months; hazard ratio [HR], 0.98; 95% CI, 0.82 to 1.16; P=0.756). However, it significantly improved PFS compared to that achieved with S-1 (median PFS, 3.9 months vs. 2.8 months; HR, 0.80; 95% CI, 0.67 to 0.95; P=0.009). Pre-planned subgroup analysis of OS showed significant interactions between the treatment effects and pancreatic resection (P=0.025), and between the treatment effects and country (P=0.004). Grade 3/4 drug-related adverse events (≥5% incidences) in TAS-118 and S-1 arms included diarrhea (7.0% vs. 7.3%), anorexia (6.7% vs. 5.0%), stomatitis (6.7% vs. 0.7%), and anemia (3.3% vs. 5.0%). Conclusions: The primary endpoint was not met. Further, the interactions between the treatment effects and pancreatic resection, and between the treatment effects and country, might affect the results. Clinical trial information: 132172. [Table: see text]" @default.
• W2892029871 created "2018-09-27" @default.
• W2892029871 creator A5001038023 @default.
• W2892029871 creator A5010090426 @default.
• W2892029871 creator A5010319344 @default.
• W2892029871 creator A5014204252 @default.
• W2892029871 creator A5015679349 @default.
• W2892029871 creator A5022537134 @default.
• W2892029871 creator A5026988448 @default.
• W2892029871 creator A5028248936 @default.
• W2892029871 creator A5037636747 @default.
• W2892029871 creator A5045587524 @default.
• W2892029871 creator A5047472576 @default.
• W2892029871 creator A5050468802 @default.
• W2892029871 creator A5050530209 @default.
• W2892029871 creator A5053847518 @default.
• W2892029871 creator A5054771200 @default.
• W2892029871 creator A5056197140 @default.
• W2892029871 creator A5065581439 @default.
• W2892029871 creator A5068601802 @default.
• W2892029871 creator A5076136934 @default.
• W2892029871 creator A5076696174 @default.
• W2892029871 date "2017-05-20" @default.
• W2892029871 modified "2023-09-22" @default.
• W2892029871 title "TAS-118 (S-1 plus leucovorin) versus S-1 in gemcitabine-refractory advanced pancreatic cancer: A randomized, open-label, phase III trial (GRAPE trial)." @default.
• W2892029871 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.4099" @default.
• W2892029871 hasPublicationYear "2017" @default.
• W2892029871 type Work @default.
• W2892029871 sameAs 2892029871 @default.
• W2892029871 citedByCount "2" @default.
• W2892029871 countsByYear W28920298712018 @default.
• W2892029871 countsByYear W28920298712019 @default.
• W2892029871 crossrefType "journal-article" @default.
• W2892029871 hasAuthorship W2892029871A5001038023 @default.
• W2892029871 hasAuthorship W2892029871A5010090426 @default.
• W2892029871 hasAuthorship W2892029871A5010319344 @default.
• W2892029871 hasAuthorship W2892029871A5014204252 @default.
• W2892029871 hasAuthorship W2892029871A5015679349 @default.
• W2892029871 hasAuthorship W2892029871A5022537134 @default.
• W2892029871 hasAuthorship W2892029871A5026988448 @default.
• W2892029871 hasAuthorship W2892029871A5028248936 @default.
• W2892029871 hasAuthorship W2892029871A5037636747 @default.
• W2892029871 hasAuthorship W2892029871A5045587524 @default.
• W2892029871 hasAuthorship W2892029871A5047472576 @default.
• W2892029871 hasAuthorship W2892029871A5050468802 @default.
• W2892029871 hasAuthorship W2892029871A5050530209 @default.
• W2892029871 hasAuthorship W2892029871A5053847518 @default.
• W2892029871 hasAuthorship W2892029871A5054771200 @default.
• W2892029871 hasAuthorship W2892029871A5056197140 @default.
• W2892029871 hasAuthorship W2892029871A5065581439 @default.
• W2892029871 hasAuthorship W2892029871A5068601802 @default.
• W2892029871 hasAuthorship W2892029871A5076136934 @default.
• W2892029871 hasAuthorship W2892029871A5076696174 @default.
• W2892029871 hasConcept C121332964 @default.
• W2892029871 hasConcept C121608353 @default.
• W2892029871 hasConcept C126322002 @default.
• W2892029871 hasConcept C141071460 @default.
• W2892029871 hasConcept C142424586 @default.
• W2892029871 hasConcept C168563851 @default.
• W2892029871 hasConcept C203092338 @default.
• W2892029871 hasConcept C207103383 @default.
• W2892029871 hasConcept C2780210213 @default.
• W2892029871 hasConcept C2780258809 @default.
• W2892029871 hasConcept C2780739268 @default.
• W2892029871 hasConcept C3019894029 @default.
• W2892029871 hasConcept C31760486 @default.
• W2892029871 hasConcept C44249647 @default.
• W2892029871 hasConcept C535046627 @default.
• W2892029871 hasConcept C71924100 @default.
• W2892029871 hasConcept C87355193 @default.
• W2892029871 hasConcept C90924648 @default.
• W2892029871 hasConceptScore W2892029871C121332964 @default.
• W2892029871 hasConceptScore W2892029871C121608353 @default.
• W2892029871 hasConceptScore W2892029871C126322002 @default.
• W2892029871 hasConceptScore W2892029871C141071460 @default.
• W2892029871 hasConceptScore W2892029871C142424586 @default.
• W2892029871 hasConceptScore W2892029871C168563851 @default.
• W2892029871 hasConceptScore W2892029871C203092338 @default.
• W2892029871 hasConceptScore W2892029871C207103383 @default.
• W2892029871 hasConceptScore W2892029871C2780210213 @default.
• W2892029871 hasConceptScore W2892029871C2780258809 @default.
• W2892029871 hasConceptScore W2892029871C2780739268 @default.
• W2892029871 hasConceptScore W2892029871C3019894029 @default.
• W2892029871 hasConceptScore W2892029871C31760486 @default.
• W2892029871 hasConceptScore W2892029871C44249647 @default.
• W2892029871 hasConceptScore W2892029871C535046627 @default.
• W2892029871 hasConceptScore W2892029871C71924100 @default.
• W2892029871 hasConceptScore W2892029871C87355193 @default.
• W2892029871 hasConceptScore W2892029871C90924648 @default.
• W2892029871 hasIssue "15_suppl" @default.
• W2892029871 hasLocation W28920298711 @default.
• W2892029871 hasOpenAccess W2892029871 @default.
• W2892029871 hasPrimaryLocation W28920298711 @default.
• W2892029871 hasRelatedWork W2024826853 @default.
• W2892029871 hasRelatedWork W2479179615 @default.
• W2892029871 hasRelatedWork W2516535717 @default.
• W2892029871 hasRelatedWork W2518765238 @default.
• W2892029871 hasRelatedWork W2596133298 @default.

• next